Physician profile
Eric David Rosenberg
NPI 1194164186
$433,568.29
in general payments reported to CMS, 2019-2025
35 companies · $146K in 2025
The $146K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,208 · 2020: $13K · 2021: $44K · 2022: $55K · 2023: $28K · 2024: $144K · 2025: $146K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $196K · Consulting Fee: $82K · Travel and Lodging: $22K · Food and Beverage: $16K · Honoraria: $2,100 · Education: $97.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $196,000.00 |
| Consulting Fee | $82,091.00 |
| Travel and Lodging | $21,977.35 |
| Food and Beverage | $16,182.32 |
| Honoraria | $2,100.00 |
| Education | $97.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $153,645.71 | 2019-2025 | Tryptyr, Ngenuity, Luxor |
| Tarsus Pharmaceuticals, INC. | $139,591.06 | 2024-2025 | Xdemvy |
| Alcon Research LLC | $59,606.00 | 2020-2025 | Ngenuity |
| Abbvie INC. | $34,943.34 | 2022-2025 | Vuity, Xen Glaucoma Treatment System, Lumigan |
| Glaukos Corporation | $9,611.42 | 2019-2025 | Travoprost Intraocular Implant - Idose, Idose |
| Beaver-Visitec International, INC. | $6,114.32 | 2022-2025 | |
| New World Medical,INC. | $5,771.64 | 2021-2025 | Kahook Dual Blade, Clearpath, Streamline |
| Carl Zeiss Meditec, INC. | $5,352.43 | 2021-2023 | Artevo 800, Veracity Surgical, Callisto Eye |
| Sight Sciences, INC. | $3,293.33 | 2019-2023 | Tearcare System |
| Eyevance Pharmaceuticals LLC | $3,227.23 | 2021-2023 | Tobradex St |
| Bausch & Lomb Americas INC. | $3,114.04 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Omeros Corporation | $1,601.41 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $1,309.01 | 2022-2025 | Acthar |
| Harrow Eye, LLC | $1,275.83 | 2024-2025 | Vevye, Triesence, Iheezo |
| Oyster Point Pharma, INC. | $868.55 | 2022-2025 | Tyrvaya |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Topcon Healthcare, INC. | $607.22 | 2024 | |
| Allergan, INC. | $540.26 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $477.88 | 2020-2023 | |
| Biotissue Holdings INC. | $455.87 | 2020-2025 | |
| Ocular Therapeutix, INC. | $427.57 | 2019-2025 | Dextenza |
| Kala Pharmaceuticals, INC. | $387.64 | 2019-2021 | |
| Dompe US, INC. | $192.26 | 2022-2025 | Oxervate |
| Lumibird Medical INC. | $166.60 | 2025 | |
| Sun Pharmaceutical Industries INC. | $165.55 | 2024-2025 | |
| Shire North American Group INC | $149.93 | 2019 | |
| Genzyme Corporation | $131.40 | 2022 | |
| Eyepoint US, INC. | $101.85 | 2022-2023 | |
| Amgen INC. | $94.18 | 2024-2025 | Tepezza |
| Carl Zeiss Meditec USA, INC. | $77.44 | 2021-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $76.15 | 2023-2025 | Veritas Vision System, Tecnis Iol, Catalys System |
| Rxsight INC | $49.82 | 2024-2025 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Rayner Intraocular Lenses Limited | $45.34 | 2023-2025 | Omidria, Rayone Emv, Rayone Aspheric |
| Thea Pharma INC. | $39.66 | 2024-2025 | Iyuzeh |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $31.62 | 2020-2021 | |
| Astellas Pharma US INC | $24.73 | 2024 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Rosenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.